Compare AFLAC Incorporated (AFL) vs Xylem, Inc. (XYL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AFLAC Incorporated vs Xylem, Inc. — how do they compare? AFLAC Incorporated trades at $121.28 (market cap $61.84B), while Xylem, Inc. trades at $118.41 (market cap $28.68B). The key difference: AFLAC Incorporated is far larger — about 2.2× Xylem, Inc.'s market cap, and AFLAC Incorporated pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AFL | XYL | |
|---|---|---|
Market Cap | $61.84B | $28.68B |
Sector | Financials | Industrials |
52-Week High | $121.49 | $152.95 |
52-Week Low | $98.09 | $106.34 |
Enterprise Value | $70.50B | $29.93B |
Dividend Yield | 2.01% | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $121.49, up 0.5% with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 25.32% net income margin and 16.47% ROE, though recent Q1 2026 earnings missed expectations. Analyst consensus is mixed with 28% buy ratings and a $113.57 price target below current levels. Recent developments include strong dividend performance and upcoming Q2 2026 results announcement on August 6, 2026.
The outlook remains cautiously optimistic with solid profitability and dividend stability, but faces headwinds from recent earnings misses and premium valuation pressure. Key opportunities include continued growth in Japan and U.S. markets, while risks involve medical cost inflation and uneven revenue trends. The stock's current premium to analyst targets suggests limited near-term upside potential.
Xylem (XYL) trades at $120.65, up 2.14% today, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. Revenue grew to $9.04B in 2025, with net income margin improving to 10.79%. Recent news highlights strategic partnerships and leadership appointments, reinforcing its position in water technology solutions.
The stock offers upside to the $153.14 consensus price target, driven by steady earnings growth and margin expansion. Risks include execution challenges in a competitive market and potential macroeconomic headwinds affecting industrial demand. Analyst sentiment is mixed but leans positive with 47.5% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
